Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Slides:

Advertisements

Similar presentations

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Advertisements

Su K. Metcalfe, MD, MPH, Michael T

Overexpression of β-Catenin and Cyclin D1 is Associated with Poor Overall Survival in Patients with Stage IA–IIA Squamous Cell Lung Cancer Irrespective.

Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma Hideyuki Imoto, MD, Toshihiro.

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang,

AZGP1 Autoantibody Predicts Survival and Histone Deacetylase Inhibitors Increase Expression in Lung Adenocarcinoma Daniel L. Albertus, BS, Christopher.

Characterization of Aurora A and Its Impact on the Effect of Cisplatin-Based Chemotherapy in Patients with Non–Small Cell Lung Cancer Peng Kuang, Zuhua.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers Yung-Chie Lee, MD, PhD, Yih-Leong Chang, MD, Shi-Ping.

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.

Osteopontin Combined With CD44v6, a Novel Prognostic Biomarker in Non-Small Cell Lung Cancer Undergoing Curative Resection Bing-sheng Sun, MD, PhD, Yue.

Co-Overexpression of Cyclooxygenase-2 and Microsomal Prostaglandin E Synthase-1 Adversely Affects the Postoperative Survival in Non-small Cell Lung Cancer

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy Apar Pataer, MD, PhD, Neda Kalhor,

High Expression of Zinc-Binding Protein-89 Predicts Decreased Survival in Esophageal Squamous Cell Cancer Shu-Mei Yan, MD, Hui-Ni Wu, MB, Fan He, MD,

Interpretation of Anti-ALK Immunohistochemistry Results

Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer David J. Stewart, MD, Maria I. Nunez, MD,

Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer Franz Blaes, MD, Markus Klotz, Hanno Huwer, MD, Uwe.

Prognostic Significance of the Tumor Suppressor Gene Maspin in Non–Small Cell Lung Cancer Kyoji Hirai, MD, Kiyoshi Koizumi, MD, Shuji Haraguchi, MD,

Osteopontin-Expressing Macrophages in Non-Small Cell Lung Cancer Predict Survival Yue Li, MD, Bing-sheng Sun, MD, PhD, Baoxiang Pei, MD, Chen-guang Li,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Deregulated p21WAF1 Overexpression Impacts Survival of Surgically Resected Esophageal Squamous Cell Carcinoma Patients Yih-Gang Goan, MD, Hon-Ki Hsu,

Jarrod D. Predina, BA, Matthew M. Puc, MD, Meredith R

Iwao Takanami, MD, Ken Takeuchi, MD, Masatoshi Giga, MD

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non–Small Cell Lung Cancer in the U.S. National Cancer Data Base

Interstitial tumor-associated macrophages combined with tumor-derived colony- stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non–small.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

Reduced membranous β-catenin protein expression is associated with metastasis and poor prognosis in squamous cell carcinoma of the esophagus Po-Kuei.

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Survival Differences by Gender for Resected Non-small Cell Lung Cancer: A Retrospective Analysis of 12,509 Cases in a Japanese Lung Cancer Registry Study

Thoracoscopic Lobectomy Produces Long-Term Survival Similar to That with Open Lobectomy in Cases of Non–Small Cell Lung Carcinoma: A Propensity-Matched.

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis.

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Expression and Mutational Status of c-kit in Thymic Epithelial Tumors

High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen.

Use of MicroRNA Expression Levels to Predict Outcomes in Resected Stage I Non- small Cell Lung Cancer Eric Duncavage, MD, Boone Goodgame, MD, Ananth Sezhiyan,

Tumor-Stroma Ratio Is an Independent Predictor for Survival in Esophageal Squamous Cell Carcinoma kai Wang, MD, Wei Ma, MD, Jianbo Wang, MD, Liang Yu,

Predictive Value of Intratumoral Microvascular Density in Patients with Advanced Non- small Cell Lung Cancer Receiving Chemotherapy Plus Bevacizumab Yuan-Yuan.

Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non- small Cell Lung Cancer Jin Hwa Lee, MD, PhD, Eun Mi Song, MD, Yun Su Sim,

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

C-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas Koji Tsuta, MD, PhD, Yoshiki Kozu, MD, PhD, Takahiro.

A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer Mian Xi, MD, Zhongxing.

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

Prognostic Significance of Aberrant Methylation of Solute Carrier Gene Family 5A8 in Lung Adenocarcinoma Koei Ikeda, MD, PhD, Kenji Shiraishi, MD, PhD,

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer Murry.

Neuronatin Expression and Its Clinicopathological Significance in Pulmonary Non-small Cell Carcinoma Teruhito Uchihara, MD, Chigusa Okubo, MS, Ryota.

Identification and Validation of Lymphovascular Invasion as a Prognostic and Staging Factor in Node-Negative Esophageal Squamous Cell Carcinoma Qingyuan.

Neal S Goldstein, MD The Annals of Thoracic Surgery

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Presentation transcript:

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD, Su-Xia Lin, MD, PhD, Zhi-Huang Hu, MD, Fei Xu, MD, Hong- Yun Zhao, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 5, Pages 799-807 (May 2012) DOI: 10.1097/JTO.0b013e318248240b Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Western blot analysis of TAZ expression in normal human bronchial epithelial (HBE) and NSCLC cell lines. Cell lysates extracted from these cell lines were subjected to Western blot using anti-TAZ and anti-β-actin antibodies. The levels of β-actin were used as internal protein loading controls. Journal of Thoracic Oncology 2012 7, 799-807DOI: (10.1097/JTO.0b013e318248240b) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Immunohistochemistry staining of TAZ in NSCLC. TAZ positive expression in both nucleus and cytoplasm of lung adenocarcinoma (A). TAZ positive expression in lung squamous carcinoma, staining in both cytoplasm and nucleus of tumor cells (B). Negative TAZ expression in lung adenocarcinoma (C). Negative expression in normal lung tissue (D). Original magnification, ×200. Journal of Thoracic Oncology 2012 7, 799-807DOI: (10.1097/JTO.0b013e318248240b) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Overall survival curves with TAZ expression results in the entire population (A), in stage I NSCLC patients (B), and in stage II/ III NSCLC patients (C). Journal of Thoracic Oncology 2012 7, 799-807DOI: (10.1097/JTO.0b013e318248240b) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Disease-free survival curves with TAZ expression results in the entire population (A), in stage I NSCLC patients (B), and in stage II/ III NSCLC patients (C). Journal of Thoracic Oncology 2012 7, 799-807DOI: (10.1097/JTO.0b013e318248240b) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Disease-free survival curve (A) and overall survival (B) among patients with TAZ positive expression. Journal of Thoracic Oncology 2012 7, 799-807DOI: (10.1097/JTO.0b013e318248240b) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Kaplan-Meier estimates of overall survival between adjuvant chemotherapy group and observation group among patients with TAZ positive expression (A) or those without TAZ expression (B). Journal of Thoracic Oncology 2012 7, 799-807DOI: (10.1097/JTO.0b013e318248240b) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions